Researchers at the University of California, Davis have developed a new and simple, label-free method to detect milligram levels of RNase activity in undiluted biological samples that is selective, accurate and scalable.
Traditionally, RNase activity of biological samples has been measured using ultraviolet based ELISAs for the detection of nucleic acids or degraded nucleosides. With limited accuracy and sensitivity, current alternative methods include the use of expensive fluorophore-labeled antibodies and dangerous radioactive isotope-labeled RNA substrates. Both these methods often require the significant dilution of high RNase containing samples into a detectable range, altering the precision and accuracy of these assay methods. Therefore, there is a need for a method that is selective, accurate, inexpensive and safe and can be used with undiluted biological samples.
Researchers at the University of California, Davis have developed a unique, fluorescence-based method for quantifying RNase activity using label-free RNA substrates produced in E. coli on a large scale. The method uses a stable analyte that, upon incubation with an RNase containing biological sample, fluoresces, allowing for the direct and specific milligram level detection of RNases in undiluted test samples. The substrates are light and temperature stable and are not active until they are in the presence of RNases. This method offers a simple and cost-effective means to measure RNase activity in undiluted biological samples without compromising sensitivity or specificity.
· Diagnosis/prognosis of RNase dysregulation in (but not limited to): serum, saliva, sweat, tears, milk, semen, urine, vaginal secretions and tissue biopsies
· Cost effective
· Easily Scalable
· Light and temperature stable reagents
· More accurate than current methods of RNase activity assay
· Selective and specific detection method
|United States Of America||Issued Patent||11,041,201||06/22/2021||2015-626|
|United States Of America||Issued Patent||10,422,003||09/24/2019||2015-626|
Method has been developed and verified in vitro in a human cell line, in vivo in a transgenic mouse model and ex vivo in human serum
RNase, label-free, chimeric RNA, diagnosis, cancer, diseases